ArticleDiscover oncology2026
Autophagy-related gene-based prognostic model for breast cancer.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeBreast cancer (BRCA), a major global health issue, has recently become the first major cancer, surpassing lung cancer, and the primary contributor to female cancer deaths. Neoadjuvant chemotherapy (NAC) serves as the standard treatment for BRCA and is associated with favorable disease-free survival (DFS) and overall survival (OS). Autophagy-related genes (ARGs) not only facilitate tumor initiation and progression but also exhibit a close correlation with chemoresistance. This study intends to explore the molecular signature for predicting the BRCA immune response and prognosis based on ARGs.
methodsWe collected RNA sequencing data of BRCA from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO), and screened prognostic genes by WCGNA, univariate Cox analysis, and LASSO regression. Then, based on 11 chemotherapy-sensitive ARGs (C-ARGs), a prognostic model was established using a multivariate Cox analysis. Subsequently, to assess the model’s performance (TCGA), we plotted receiver operating characteristic (ROC) curves and conducted external validation (GEO).
resultsWe found that for 1-/3-/5-year overall survival, the areas under the ROC curve (AUCs) were 0.654, 0.673, and 0.698 in the TCGA training cohort, and 0.641, 0.719, and 0.749 (GSE42568) and 0.635, 0.742, and 0.702 (GSE20685) in the GEO validation cohort. The results demonstrated the satisfactory performance of the C-ARG-based model in predicting the efficacy and BRCA prognosis. In addition, in the low-/high-risk groups, the proportion of immune subtypes and the IC50 value significantly differed, which can guide the systemic therapy.
conclusionThe C-ARG-based prognostic model exhibits excellent performance in predicting the BRCA prognosis, which lays a solid foundation for the development of clinical treatment protocols for BRCA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.